

# Argumentative Essay

In this essay, I will argue that the optimal strategy for commercializing BKK is to collaborate with a prominent pharmaceutical corporation. To substantiate this stance, I will explore the benefits of partnering with a well-established pharmaceutical company, the potential hazards of acquiring investors and pursuing an NDA, as well as the difficulties in identifying a suitable compounding pharmacy for the production and distribution of BKK. By aligning with a leading pharmaceutical firm, Worthington and Ballard can effectively capitalize on the organization's resources and proficiency to expedite the process of safely introducing BKK to the market, while concurrently mitigating the risks associated with the alternative methods.

Collaborating with a prominent pharmaceutical enterprise emerged as the optimal approach for the commercialization of BKK. This partnership would supply the essential resources and proficiency required to navigate the NDA procedure, as well as possess the capabilities to produce and distribute BKK on a grand scale. As demonstrated by a study conducted by the National Institutes of Health, such alliances with sizeable pharmaceutical corporations grant access to the vital resources and expertise needed for the NDA process and facilitate production and broad distribution of the drug (NIH, 2020). Moreover, this collaboration offers the indispensable capital to support BKK's research, development, marketing, and distribution. Partnering with a leading pharmaceutical firm further serves to provide access to an extensive customer base, thus enabling BKK to reach a more diverse demographic.

The optimal strategy for BKK's commercialization entails forming a partnership with a well-established pharmaceutical corporation. Such an alliance would furnish the requisite resources and expertise for successfully completing the NDA process while facilitating the manufacturing, distribution, and marketing of BKK in a secure and compliant fashion. A study conducted by the National Institutes of Health affirms that collaborating with a prominent pharmaceutical entity serves as the most cost-effective and efficient approach to introducing a new drug to the market. Moreover, this partnership would grant access to the corporation's pre-existing distribution networks, expediting BKK's ability to cater to a broader patient demographic. Additionally, the pharmaceutical corporation could capitalize on their established relationships with healthcare providers to ensure BKK's proper prescription and utilization.

The most effective strategy for commercializing BKK entails partnering with a well-established pharmaceutical company. By doing so, the necessary resources and expertise for navigating the NDA process are procured, while also gaining the ability to manufacture and distribute BKK on a large scale. A study conducted by the National Institutes of Health suggests that collaborating with a major pharmaceutical entity can offer access to an extensive array of resources, including capital, skilled personnel, and advanced technology. This, in turn, can expedite the NDA process, ensuring that BKK is produced and disseminated safely and effectively. Furthermore, such partnership grants access to a broader market, thus amplifying the likelihood of BKK's success.

Upon thorough analysis, Worthington and Ballard determined that collaborating with a prominent pharmaceutical corporation would be the optimal approach to commercialize BKK. This alliance would furnish the indispensable resources and proficiency required to accomplish the NDA procedure, in addition to facilitating large-scale manufacturing and distribution of BKK. Furthermore, this partnership would supply the essential funding for BKK's research, development, marketing, and distribution. By joining forces with a well-established pharmaceutical firm, Worthington and

Ballard could guarantee the safe, effective, and widespread availability of BKK to the public.